 Palforzia, approved in late January and priced at 890 per month, is designed to reduce sensitivity to peanuts by exposing patients to refined version of peanut flour over time. Palforzia received approval based on data from a pivotal trial where patients who received the drug for six months showed greater tolerance to peanut protein, compared to placebo. Aimmune in March warned of a slow launch of the peanut allergy therapy, as its marketing plans take a hit from U.S. authorities recommendation of social distancing to contain the spread of the coronavirus. 